OMER News and Press, Omeros Corporation From 04/20/22

Omeros Corporation (Nasdaq: OMER) today announced the online publication of a manuscript detailing the results of its pivotal study assessing efficacy and safety of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), an o...

Referring to the most up-to-date market data as of Apr. 11, Cantor Fitzgerald has listed the biotech companies with the most notable changes in the short interest. The nano-cap commercial-stage pharma company, Clarus Therapeutics (CRXT) dominates the list with over ten times increase in short...

Omeros Corporation (OMER) Q4 2021 Earnings Conference Call March 1, 2022 4:30 P.M. ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman and Chief Executive Officer Mike Jacobsen - Chief Accounting Officer Cathy Melfi - Chief Regulatory Officer Steve Whitake...

Omeros press release (NASDAQ:OMER): Q4 Non-GAAP EPS of -$0.37 misses by $0.31. At December 31, 2021, Omeros had $157.3 million of cash, cash equivalents and short-term investments available for operations and $38.2 million in accounts receivable, all of which is expected to be collected this ...

– Conference Call Today at 4:30 p.m. ET – Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indicatio...

Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2021, on Tuesday, March 1, 2022, after the market closes. Omeros management will host a conference call and webcast that day ...

Omeros was handed a CRL for narsoplimab. The lack of clarity surrounding the CRL is disconcerting. I will stay on the sidelines despite the seemingly attractive price. For further details see: Omeros: Despite Its Promise, The CRL Is A Huge Obstacle

Omeros Corporation (Nasdaq: OMER) today confirmed that earlier this month the company submitted to the U.S. Food and Drug Administration (FDA) its response to the Agency’s Complete Response Letter (CRL) for narsoplimab in the treatment of hematopoietic stem cell transplant-associ...

Omeros Corporation (Nasdaq: OMER) today announced that it has completed the sale of OMIDRIA (phenylephrine and ketorolac intraocular solution) 1.0%/0.3% to Rayner Surgical Group Inc . , an affiliate of Rayner Surgical Group Limited. The transaction was completed pursuant to an Asset...

Intercontinental Exchange will add 138 securities to the ICE Biotechnology index and delete 26 as part of the annual reconstitution, effective prior to market open on December 20. Notable additions: Aurinia Pharmaceuticals (NASDAQ:AUPH), Anavex Life Sciences (NASDAQ:AVXL), Sesen Bio...